PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

DOAC After LAAC Beats DAPT Only in Observational Data

direct oral anticoagulantsDOACdual antiplatelet therapyDAPTleft atrial appendage closureLAACnon-valvular atrial fibrillationdevice-related thrombosismeta-analysisanticoagulationbleedingstroke prevention Anticoagulation / Hematology
Also in Cardiology

Background Information

DOACs may outperform DAPT after LAAC in NVAF patients.

The optimal antithrombotic strategy after left atrial appendage closure (LAAC) in patients with non-valvular atrial fibrillation (NVAF) remains uncertain, impacting patient outcomes. Direct oral anticoagulants (DOACs) reduced all-cause mortality, major bleeding, and device-related thrombosis compared to dual antiplatelet therapy (DAPT) in a pooled analysis; benefits were not statistically significant in randomized trials alone. DOACs may offer advantages over DAPT in terms of safety and efficacy after LAAC, but caution is advised as benefits were primarily observed in non-randomized studies. DOACs could reduce mortality and complications after LAAC but need further evidence from randomized trials.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Alam U, Ahmed AU, Javed J, Khan A, Ansab M, Khan I, Rafi S, Mushahid Z, Nawaz B, Asif MA, Lohana R, Khan SN, Moiz A, Bibi F, Aslam B

Citation: Alam U, Ahmed AU, Javed J, et al. Direct oral anticoagulant dose vs dual antiplatelet therapy after left atrial appendage closure in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis. Journal of thrombosis and thrombolysis. 2026. doi:10.1007/s11239-026-03381-6

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.